Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  UniQure N.V.    QURE   NL0010696654

UNIQURE N.V.

(QURE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/06/2020 07/07/2020 07/08/2020 07/09/2020 07/10/2020 Date
44.81(c) 45.74(c) 46.82(c) 47.66(c) 46.41(c) Last
760 609 562 134 267 521 585 163 366 706 Volume
-1.60% +2.08% +2.36% +1.79% -2.62% Change
More quotes
Financials
Sales 2020 96,4 M 109 M 109 M
Net income 2020 0,94 M 1,06 M 1,06 M
Net cash position 2020 306 M 346 M 346 M
P/E ratio 2020 -232x
Yield 2020 -
Sales 2021 63,6 M 72,1 M 72,1 M
Net income 2021 -64,2 M -72,7 M -72,7 M
Net cash position 2021 325 M 369 M 369 M
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 1 820 M 2 056 M 2 061 M
EV / Sales 2020 15,7x
EV / Sales 2021 23,5x
Nbr of Employees 248
Free-Float 94,8%
More Financials
Company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a... 
More about the company
Surperformance© ratings of uniQure N.V.
Trading Rating : Investor Rating :
More Ratings
Latest news on UNIQURE N.V.
06/24UNIQURE N : in License Deal With CSL Behring to Commercialize Hemophilia Therapy
DJ
06/24uniQure Announces License Agreement with CSL Behring to Commercialize Hemophi..
GL
06/19uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of ..
GL
06/17uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of D..
GL
06/15uniQure Announces Change for its 2020 Annual General Meeting of Shareholders
GL
05/14uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia ..
GL
04/29uniQure Announces First Quarter 2020 Financial Results and Highlights Recent ..
GL
04/17uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Di..
GL
03/30uniQure to Participate in Multiple Upcoming Investor Conferences in April
GL
03/26uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Tria..
GL
03/03uniQure to Participate in Multiple Upcoming Industry Conferences in March
GL
03/02uniQure and Gen-X Enter into Research Collaboration and License Agreement for..
GL
03/02uniQure Announces 2019 Financial Results and Highlights Recent Company Progre..
GL
02/27uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI's 15th ..
GL
02/04uniQure Announces Presentations at the Upcoming 13th Annual Congress of the E..
GL
More news
News in other languages on UNIQURE N.V.
06/24UNIQURE N : in License Deal With CSL Behring to Commercialize Hemophilia Therapy
06/24uniQure Announces License Agreement with CSL Behring to Commercialize Hemophi..
06/19uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of ..
06/17uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of D..
06/15uniQure Announces Change for its 2020 Annual General Meeting of Shareholders
More news
Chart UNIQURE N.V.
Duration : Period :
uniQure N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UNIQURE N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 67,15 €
Last Close Price 41,08 €
Spread / Highest target 102%
Spread / Average Target 63,4%
Spread / Lowest Target 21,0%
EPS Revisions
Managers
NameTitle
Matthew C. Kapusta CEO, Chief Financial Officer & Executive Director
Philip Astley-Sparke Chairman
Alexander E. Kuta Executive Vice President-Operations
Sander J. van Deventer Executive VP-Research & Product Development
Robert Gut Executive Director & Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
UNIQURE N.V.-35.24%2 056
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955